In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

BACKGROUND: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we compared tumour vessel remodelling and reoxygenation between the two agents. METHODS: Patients with advance...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Cancer
Päätekijät: Ueda, Shigeto, Saeki, Toshiaki, Takeuchi, Hideki, Shigekawa, Takashi, Yamane, Tomohiko, Kuji, Ichiei, Osaki, Akihiko
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2016
Aiheet:
Translational Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891505/
https://ncbi.nlm.nih.gov/pubmed/27140309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.122
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia